INT183888

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.49
First Reported 2005
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 6
Total Number 6
Disease Relevance 1.62
Pain Relevance 0.08

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (PAF1)
Anatomy Link Frequency
HPAF-II 1
BxPC-3 1
PAF1 (Homo sapiens)
Pain Link Frequency Relevance Heat
tolerance 7 86.40 High High
Pain 6 33.84 Quite Low
cva 16 19.60 Low Low
Inflammation 4 13.52 Low Low
beta blocker 17 5.00 Very Low Very Low Very Low
amygdala 8 5.00 Very Low Very Low Very Low
medulla 8 5.00 Very Low Very Low Very Low
Angina 6 5.00 Very Low Very Low Very Low
Chronic pancreatitis 4 5.00 Very Low Very Low Very Low
fibrosis 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Adenocarcinoma 102 98.52 Very High Very High Very High
Death 187 94.00 High High
Heart Rate Under Development 37 84.08 Quite High
Arrhythmia Under Development 21 81.28 Quite High
Polycystic Ovary Syndrome 3 57.16 Quite High
Arrhythmias 2 Under Development 34 53.40 Quite High
Emergencies 21 50.00 Quite Low
Pancreatic Cancer 14 50.00 Quite Low
Pain 6 33.84 Quite Low
Cv General 3 Under Development 12 19.60 Low Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Expression of cav-1 was increased 3.1-fold in the HPAF-II/dnRhoC cells compared with the parental HPAF-II and vector control cells.
Positive_regulation (increased) of HPAF in HPAF-II
1) Confidence 0.49 Published 2005 Journal Mol Cancer Section Body Doc Link PMC1173138 Disease Relevance 0.18 Pain Relevance 0
Treatment with SB220025 increased cav-1 expression dramatically in the HPAF-II and slightly in the BxPC-3 cells, implying a reciprocal relationship between cav-1 expression and p38 activation.
Positive_regulation (increased) of HPAF in BxPC-3
2) Confidence 0.45 Published 2005 Journal Mol Cancer Section Body Doc Link PMC1173138 Disease Relevance 0.30 Pain Relevance 0
The 89 PD2i-rejected patients, of the 819 patients with complete data (10.86%), were rejected by both the Randomized Phase Surrogate Test (inverse Fourier with random phases) and the %N Test (% accepted PD2i/total PD2i).
Positive_regulation (accepted) of PD2i
3) Confidence 0.32 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621378 Disease Relevance 0.30 Pain Relevance 0
These two PD2i patterns each indicate PD2i ?
Positive_regulation (indicate) of PD2i
4) Confidence 0.32 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621378 Disease Relevance 0.42 Pain Relevance 0
The 89 PD2i-rejected patients, of the 819 patients with complete data (10.86%), were rejected by both the Randomized Phase Surrogate Test (inverse Fourier with random phases) and the %N Test (% accepted PD2i/total PD2i).
Positive_regulation (accepted) of PD2i
5) Confidence 0.32 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621378 Disease Relevance 0.30 Pain Relevance 0
For values of PD2i that lie in the transition zone between 1.6 and 1.4 (the cut-point, ROC area = 0.91)16 very small amounts of low-level noise can falsely increase low PD2i’s into this region; if data files had such transition zone PD2i scores, then a transition zone algorithm (TZA) was applied: if the mean PD2i was highly reduced from normal with >75% of the PD2i’s being below 3.0, then 0.2 degrees of freedom (dimension) was subtracted from each PD2i value.


Positive_regulation (increase) of PD2i
6) Confidence 0.02 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2731023 Disease Relevance 0.11 Pain Relevance 0.08

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox